Market capitalization | $440.63m |
Enterprise Value | $325.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 25.26 |
P/S ratio (TTM) P/S ratio | 34.24 |
P/B ratio (TTM) P/B ratio | 3.98 |
Revenue growth (TTM) Revenue growth | 34.05% |
Revenue (TTM) Revenue | $12.87m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
11 Analysts have issued a Taysha Gene Therapies Inc forecast:
11 Analysts have issued a Taysha Gene Therapies Inc forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -112 -112 |
33%
33%
|
|
Depreciation and Amortization | 1.37 1.37 |
45%
45%
|
|
Stock Compensation | 7.91 7.91 |
56%
56%
|
|
Operating Cash Flow | -73 -73 |
17%
17%
|
|
Investments | 7.37 7.37 |
70%
70%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -77 -77 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
Head office | United States |
CEO | Sean Nolan |
Employees | 52 |
Founded | 2019 |
Website | www.tayshagtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.